IBRX

ImmunityBio, Inc.

4.70 USD
-0.01 (-0.21%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

ImmunityBio, Inc. stock is up 28.77% since 30 days ago. The next earnings date is Mar 15, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 22.22% of the previous 8 March’s closed higher than February. In the last 10 Unusual Options Trades, there were 10 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
29 Feb 18:16 19 Apr, 2024 2.50 CALL 200 2196
29 Feb 18:16 19 Apr, 2024 2.50 CALL 233 2196
29 Feb 18:16 19 Apr, 2024 2.50 CALL 300 2196
29 Feb 19:09 19 Apr, 2024 3.00 CALL 200 1949
29 Feb 19:09 19 Apr, 2024 3.00 CALL 444 1949
29 Feb 19:09 19 Apr, 2024 3.00 CALL 355 1949
29 Feb 20:46 19 Apr, 2024 4.50 CALL 1000 2335
29 Feb 20:49 15 Mar, 2024 4.00 CALL 999 2097
29 Feb 20:53 15 Mar, 2024 4.00 CALL 783 2097
29 Feb 20:53 15 Mar, 2024 4.00 CALL 1000 2097

About ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers.